Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-04-09 Sale |
2021-04-13 4:13 pm |
Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner |
30,928 | $21.9 | $677,357 | 7,105,800 (Indirect) |
View |
| 2021-04-07 Sale |
2021-04-09 4:47 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC 10% Owner |
41,982 | $30.99 | $1,300,850 | 6,020,238 (Indirect) |
View |
| 2021-01-12 Purchase |
2021-01-14 5:54 pm |
Cullinan Management Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
300,000 | $21 | $6,300,000 | 7,913,887 (Direct) |
View |
| 2020-10-06 Purchase |
2020-10-08 6:26 pm |
Oncorus Inc. | ONCR | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
151,224 | $15 | $2,268,360 | 2,377,025 (Direct) |
View |
| 2020-07-28 Purchase |
2020-07-30 08:00 am |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. Director 10% Owner |
320,000 | $19 | $6,080,000 | 2,355,557 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-04-07 Other |
2021-04-09 4:47 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC 10% Owner |
15,670 | $0 | 6,020,238 (Indirect) |
View |
| 2021-01-12 Conversion |
2021-01-14 5:54 pm |
N/A N/A |
Cullinan Management Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
7,613,887 | $0 | 7,913,887 (Direct) |
View |
Ownership(A) |
2021-01-14 5:49 pm |
N/A N/A |
Cullinan Management Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
0 | $0 | 7,613,887 (Direct) |
View |
| 2020-10-06 Conversion |
2020-10-08 6:26 pm |
N/A N/A |
Oncorus Inc. | ONCR | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
2,225,801 | $0 | 2,377,025 (Direct) |
View |
Ownership |
2020-10-01 7:23 pm |
N/A N/A |
Oncorus Inc. | ONCR | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner |
0 | $0 | 2,252,947 (Direct) |
View |
| 2020-07-28 Conversion |
2020-07-30 08:00 am |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. Director 10% Owner |
23,558,112 | $0 | 2,355,557 (Indirect) |
View |
Ownership |
2020-07-23 7:22 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. Director 10% Owner |
0 | $0 | 5,742,220 (Indirect) |
View |